-
Twitch sparks gamers' wrath with Amazon AI sharing deal
-
Tielemans apologises for offending Villa fans with Man Utd boast
-
Blaze forces families to abandon Turkish tour boat
-
Stocks gain as US inflation worries ease, oil slips
-
'If you can, move!' say Rome's viral dancing seniors
-
Heavy rain soaks eastern Japan, prompting highest-level warning
-
Zambia voters weigh Hichilema's economic record
-
Celtic boss O'Neill 'much better' after hospital procedure
-
SBCFX to Showcase Trading Innovation, Regional Growth Strategy, and Future Vision at iFX EXPO Asia 2026
-
MEXC July TradFi Trading Shifts Toward AI Storage as SNDK Futures Volume Surges More Than 15x Times
-
Hodgkinson sets up Werro showdown after Euro 800m drama
-
Maghreb sees demographic shift with fertility at historic low
-
'How many will die?': the mysterious ailment killing Kenyan elephants
-
European stocks gain as oil prices ease
-
Arteta coy over Lewis-Skelly's Arsenal future after 'emotional' celebration
-
Infantino future should be decided by election says African football chief
-
Romania shuts down nuclear plant as Danube drops
-
Man City star Doku signs five-year contract extension
-
German steel giant Thyssenkrupp weighs options as Rhine drops
-
Fabien Barthez joins Zidane's new France coaching setup
-
US ambassador denounces settler siege as Israel dispatches troops
-
Taiwan chokes mobile internet speeds in drill for Chinese attack
-
Hasan takes 6-55 as Bangladesh claim opening day of Australia Test
-
From Chinese AI to Global ETFs: STARTRADER Launches 45 New 24/7 Stock and ETF CFDs
-
Taiwan says AI agents used in cyberattacks targeting island
-
Tech stocks enjoy rebound after US inflation on mixed day for markets
-
Japan protests Putin's first visit to disputed islands
-
Hasan takes 6-55 as Bangladesh bundle out Australia for 198
-
Kiss wants fit-again Wallabies playmaker Gordon to 'open up' Japan
-
Swiatek sinks Svitolina to set up Rybakina title clash in Toronto
-
British eccentrics push humble garden shed to new heights
-
Australia's Pallister shines, mixed relay record falls as Pan Pacs open
-
Zambia votes with president's economic record on the line
-
Hasan puts Bangladesh in charge as Australia struggle to 183-8
-
Germany's dry rivers spark battle on engineering vs restoration
-
Putin visits Kuril islands claimed by Japan
-
Senators demand inquiry into conditions aboard USS Abraham Lincoln
-
Swiatek downs Svitolina to reach first WTA final of 2026
-
All Blacks' Proctor out of South Africa series, Mo'unga called up
-
Jones says Japan 'watching videos of geese' for Australia clash
-
Bangladesh quick Hasan reduces Australia to 74-4 at lunch
-
Bloodied but unbowed, defending champ Shelton reaches Montreal final
-
Seoul tech leads Asian stock gains as traders cheer US inflation
-
Wallabies make eight changes for return Japan Test
-
Farage and Count Binface go head-to-head in snap UK poll
-
Messi returns after father's death but Miami knocked out of Leagues Cup
-
Afghan students divided over smartphone ban at universities
-
Outflanked by AI, stars fade for South Korea's blind fortune-tellers
-
Japan go back to school for second Australia Test
-
Venezuela govt, opposition wrap up round of post-Maduro talks
Science of sleep: Why a good night's rest gets harder with age
It's well known that getting a good night's sleep becomes more difficult as we age, but the underlying biology for why this happens has remained poorly understood.
A team of US scientists has now identified how the brain circuitry involved in regulating sleepfulness and wakefulness degrades over time in mice, which they say paves the way for better medicines in humans.
"More than half of people 65 and older complain about the quality of sleep," Stanford University professor Luis de Lecea, who co-authored a study about the finding published Thursday in Science, told AFP.
Research has shown that sleep deprivation is linked to an increased risk of multiple poor health outcomes, from hypertension to heart attacks, diabetes, depression and a build up of brain plaque linked to Alzheimer's.
Insomnia is often treated with a class of drugs known as hypnotics, which include Ambien, but these don't work very well in the elderly population.
For the new study, de Lecea and colleagues decided to investigate hypocretins, key brain chemicals that are generated only by a small cluster of neurons in the brain's hypothalamus, a region located between the eyes and ears.
Of the billions of neurons in the brain, only around 50,000 produce hypocretins.
In 1998, de Lecea and other scientists discovered that hypocretins transmit signals that play a vital role in stabilizing wakefulness.
Since many species experience fragmented sleep as they grow old, it's hypothesized that the same mechanisms are at play across mammals, and prior research had shown degradation of hypocretins leads to narcolepsy in humans, dogs and mice.
The team selected young (three to five months) and old mice (18 to 22 months) and used light carried by fibers to stimulate specific neurons. They recorded the results using imaging techniques.
What they found was that the older mice had lost approximately 38 percent of hypocretins compared to younger mice.
They also discovered that the hypocretins that remained in the older mice were more excitable and easily triggered, making the animals more prone to waking up.
This might be because of the deterioration over time of "potassium channels," which are biological on-off switches critical to the functions of many types of cells.
"The neurons tend to be more active and fire more, and if they fire more, you wake up more frequently," said de Lecea.
Identifying the specific pathway responsible for sleep loss could lead to better drugs, argued Laura Jacobson and Daniel Hoyer, of Australia's Florey Institute of Neuroscience and Mental Health, in a related commentary article.
Current treatments, such as hypnotics, "can induce cognitive complaints and falls," and medicines that target the specific channel might work better, they said.
These will need to be tested in clinical trials -- but an existing drug known as retigabine, which is currently used to treat epilepsy and which targets a similar pathway -- could be promising, said de Lecea.
Y.AlMasri--SF-PST